Novavax Inc (NVAX)
$146.20 3.10 (2.17%)
8:54 EDT NVAX Stock Quote Delayed 30 Minutes
Previous Close $143.10
Market Cap 55.80B
PE Ratio -239.67
Volume (Avg. Vol.) 37,095
Day's Range 143.10 - 143.10
52-Week Range 3.54 - 154.70
Dividend & Yield N/A (N/A)
NVAX Stock Predictions, Articles, and Novavax Inc News
- From InvestorPlace
- From the Web
Novavax (NASDAQ:NVAX) looks on its way to a credible vaccine. If so, NVAX stock going to $200 by the end of the years seems all but certain.
Novavax has been one of the companies cashing in on the race to find a vaccine against COVID-19. As a result NVAX stock is up over 3,000% year-to-date
There’s no doubting that Novavax offers an exciting new technology for a coronavirus vaccine candidate. However, NVAX stock is a trickier once you look beyond the headlines.
While it’s no guarantee that NVAX stock will be the ultimate winner from a Covid-19 vaccine, investors should pay attention to Novavax.
By Ian Cooper
While NVAX stock could race higher on news in coming days of its clinical trials results, play this one safe with a trailing stop loss to safeguard any wins you have to date.
Nio, Penn National Gaming, Amazon and Novavax were our top stock trades for Monday. That said, let's take a look at the charts.
Investors are eyeing clinical results later this month and later this year before committing to buying more NVAX stock.
AbbVie, Livongo, Walmart and Novavax were our top stock trades for Wednesday. That said, let's look at the charts to see what's going on.
Covid-19 vaccine stocks are on fire, but many of them appear to be out over their skis, including the group's hottest name, NVAX stock.
A race to develop a coronavirus vaccine is on, and these red-hot Covid-19 vaccine stocks are leading the way.
Uber, Novavax, DraftKings and Aurora Cannabis were our top stock trades for Wednesday. Let's have a look at what the charts say.
Novavax (NVAX) news for Tuesday concerning funding for a vaccine to stop the novel coronavirus has NVAX stock rocketing higher.
Novavax (NVAX) news for Wednesday concerning a trial for a vaccine to treat the coronavirus from China has NVAX stock flying high.
Investors began buying up NVAX shares in anticipation of the Phase 3 clinical trial announcement. We wound up with a 130% gain on the trade.
Unlike the broader market, these stocks to buy have managed to hold up strong amid the ongoing public health crisis.
Wall Street pros recommend making an investment decision based on multiple factors rather than just a single metric like fundamentals.
Novavax (NVAX) earnings for the vaccine company's fiscal fourth quarter of 2019 have NVAX stock heading higher after-hours Wednesday.
From The Motley Fool
Navellier RatingsPowered by Portfolio Grader